These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 9801503)
61. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis]. Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225 [TBL] [Abstract][Full Text] [Related]
62. [Human recombinant erythropoietin in treatment of uremic anemia in children with continual ambulatory peritoneal dialysis]. Litwin M; Boguszewska-Baczkowska A; Jelonek A Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):135-6. PubMed ID: 8090665 [TBL] [Abstract][Full Text] [Related]
63. A protocol for coadministration of i.v. iron dextran and heparin in chronic hemodialysis patients. Davis P; Bednarz D; Briglia A; Paganini EP ANNA J; 1998 Oct; 25(5):533-8. PubMed ID: 9887705 [TBL] [Abstract][Full Text] [Related]
64. Impact of erythropoietin on the dialysis prescription. Van Wyck DB Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083 [TBL] [Abstract][Full Text] [Related]
65. Iron management during recombinant human erythropoietin therapy. Van Wyck DB Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026 [TBL] [Abstract][Full Text] [Related]
66. Impact of inflammation on nutrition, iron status, and erythropoietin responsiveness in ESRD patients. Bistrian BR; Carey LA Nephrol Nurs J; 2000 Dec; 27(6):616-22. PubMed ID: 16649343 [TBL] [Abstract][Full Text] [Related]
68. Quality of life and hematocrit level. Levin NW Am J Kidney Dis; 1992 Jul; 20(1 Suppl 1):16-20. PubMed ID: 1626552 [TBL] [Abstract][Full Text] [Related]
69. Erythropoietin treatment in children with renal failure. Van Damme-Lombaerts R; Herman J Pediatr Nephrol; 1999 Feb; 13(2):148-52. PubMed ID: 10229005 [TBL] [Abstract][Full Text] [Related]
73. Comparative analysis between centrifuged hematocrit and "point-of-care" hemoglobin: impact on erythropoietin dosing. Marooney M ANNA J; 1998 Oct; 25(5):479-81. PubMed ID: 9887700 [TBL] [Abstract][Full Text] [Related]
74. The use of Health Care Financing Administration data for the development of a quality improvement project on the treatment of anemia. Eggers PW; Greer J; Jencks S Am J Kidney Dis; 1994 Aug; 24(2):247-54. PubMed ID: 8048432 [TBL] [Abstract][Full Text] [Related]
76. Management of anemia. Rao M; Muirhead N; Buoncristiani U Contrib Nephrol; 2004; 145():69-74. PubMed ID: 15496793 [No Abstract] [Full Text] [Related]
77. Cardiovascular effects of increasing hemoglobin in chronic renal failure. Mayer G; Hörl WH Am J Nephrol; 1996; 16(4):263-7. PubMed ID: 8739276 [TBL] [Abstract][Full Text] [Related]
78. Addressing the challenges of renal anaemia: how nurses can make a difference. Macdonald J J Ren Care; 2007; 33(4):182-6. PubMed ID: 18298037 [TBL] [Abstract][Full Text] [Related]
79. Anemia in heart failure: implications, management, and outcomes. Paul S; Paul RV J Cardiovasc Nurs; 2004; 19(6 Suppl):S57-66. PubMed ID: 15529075 [TBL] [Abstract][Full Text] [Related]
80. Higher haematocrit levels: do they improve patient outcomes, and are they cost effective? Collins AJ; Keane WF Nephrol Dial Transplant; 1998 Jul; 13(7):1627-9. PubMed ID: 9681700 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]